[{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Finnish Funding Agency for Innovation","pharmaFlowCategory":"D","amount":"$10.9 million","upfrontCash":"$1.2 million","newsHeadline":"Valo Therapeutics Announces New Funding for Immuno-Oncology Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Valo Therapeutics"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Significant Progress of SACT-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Aptorum"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"F-star Therapeutics"},{"orgOrder":0,"company":"Almac Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Almac Group"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"F-star Therapeutics"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"F-star Therapeutics: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"F-star Therapeutics"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Touchlight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Cancer Research"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector\u00ae Platform for Next Generation CAR-T Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Oxford Biomedica"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$453.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta and LG Chem Life Sciences Expand Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Sixfold Bioscience","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sixfold Bioscience and Medicines Discovery Catapult Awarded Innovate Uk Grant to Pursue Ground-Breaking Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Sixfold Bioscience"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Papyrus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Oxford Biomedica"},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent Allowance for Sareum\u2019s SDC-1802 TYK2\/JAK1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sareum"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bicycle Therapeutics"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Announces Further Uk Government Funding for Further Development of A Novel Ig E Antibody Cancer Immunotherapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Epsilogen"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STORM Therapeutics Selects First-in-Class Clinical Candidate Targeting METTL3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Storm Therapeutics"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bicycle Therapeutics"},{"orgOrder":0,"company":"Sentinel Oncology","sponsor":"PharmaEngine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sentinel Oncology"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Oracle Cancer Trust","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Target Thyroid Cancer with Triple Threat Drug Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"The Institute of Cancer Research"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Submission of Clinical Trial Application for AVA6000 Pro-Doxorubixin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evgen Pharma Announces Positive Pre-Clinical Data in Glioma for Lead Asset SFX-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evgen Pharma"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta Enters License Agreement with POINT Biopharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$15.3 million","upfrontCash":"Undisclosed","newsHeadline":"Evgen Pharma Announces Placing and Open Offer to raise up to \u00a311 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evgen Pharma"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I Clinical Trial Authorisation for AVA6000 Approved by MHRA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Storm Therapeutics Publishes Data in Nature Showing its METTL3 Inhibitor Drug Is Effective as a New Therapeutic Strategy Against AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Storm Therapeutics"},{"orgOrder":0,"company":"Adaptate Biotherapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptate Biotherapeutics Raises $18 Million in Series A2 Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Adaptate Biotherapeutics"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"OncoTEX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoTEX and Sterling Pharma Solutions Sign Clinical Manufacturing Agreement for the Development of Novel Treatment Against Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sterling Pharma Solutions"},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"Mirae Asset Capital","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iksuda Therapeutics Closes $47 Million Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Iksuda Therapeutics"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Pol\u03b8 Polymerase Inhibitor in Nature Communications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Artios Pharma Limited"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbiotica\u2019s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Microbiotica"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data for Small Molecule GPR65 Inhibitor in Human PDX Cancer Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pathios Therapeutics"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$153.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artios $153 Million (\u00a3110 Million) Series C Financing Led by Omega Funds and TCG X","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Artios Pharma Limited"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Tiziana Life Sciences"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$453.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication Of Data On SFX-01 In Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evgen Pharma"},{"orgOrder":0,"company":"Adaptate Biotherapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (\u03b3\u03b4) T Cell Engager Therapies Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Adaptate Biotherapeutics"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx\u2019s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Aptorum"},{"orgOrder":0,"company":"Varsity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Varsity Pharmaceuticals"},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Iksuda Therapeutics"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Flerie Invest","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Microbiotica Raises \u00a350m ($67m) to Advance Pipeline of Microbiome-based Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Microbiotica"},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Exscientia"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Stimunity","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Portage Biotech"},{"orgOrder":0,"company":"Ixaka","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ixaka Expands IP Portfolio to Enable Use of Targeted Nanoparticle in vivo Gene Delivery Technology With Any Cargo in Any Therapeutic Area","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ixaka"},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Exscientia"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Portage Biotech"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"International Society for Cell & Gene Therapy Presentations Illustrate Evox Therapeutics Proprietary Exosome Engineering Platform with New Data on Exosome Targeting and In Vivo Distribution","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Evox Therapeutics"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Agenus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Oxford Biotherapeutics"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evox Therapeutics Presents Progress Across its Deliverex\u2122Exosome Therapeutics Platform with Nine Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Evox Therapeutics"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Immunogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Oxford Biotherapeutics"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Renews License Triggering Payment to Avacta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxilio OXL001 Formulation Optimisation and Clinical Trial Preparation Contract with Quotient Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Quotient Sciences"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Exscientia"},{"orgOrder":0,"company":"Theolytics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theolytics Presents CAF-Targeting Therapy For Stromal Rich Tumours, And Strengthens Leadership Team","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Theolytics"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Exscientia"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Pathios Therapeutics"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Portage Biotech"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Achilles Therapeutics"},{"orgOrder":0,"company":"Immunocore","sponsor":"Gadeta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (\u03b3\u03b4) TCR ImmTAC for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immunocore"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Starbloom Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences Investors Increase Investment in LIfT and Johnson and Johnson Welcomes LIfT into JLABS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LIfT Biosciences"},{"orgOrder":0,"company":"NeoPhore","sponsor":"CRT Pioneer Fund","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Completes Extension To Series B Financing To Further Advance Discovery Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"NeoPhore"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Storm Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Storm Therapeutics"},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"KHAN Technology Transfer Fund I","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Secures \u00a32.4m ($2.9m) Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Nodus Oncology"},{"orgOrder":0,"company":"SiSaf","sponsor":"University of Leipzig","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"SiSaf"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Minaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LIfT Biosciences"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIfT BioSciences Announces Breakthrough Preclinical Data Demonstrating the Dual Mode of Action Commonly Believed Necessary for Curing Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LIfT Biosciences"},{"orgOrder":0,"company":"Cannabotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoRix's Breast Cancer Integrative Solution Demonstrated Enhanced Efficacy when Combined with Chemotherapy in An Ex-Vivo Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Cannabotech"},{"orgOrder":0,"company":"Mosaic Therapeutics","sponsor":"Syncona Investment Management","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mosaic Therapeutics Closes $28m Series A Funding and Appoints Brian Gladsden as CEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Mosaic Therapeutics"},{"orgOrder":0,"company":"NeoPhore","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"NeoPhore"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIfT Biosciences Announces Data Demonstrating Potent Killing of Pancreatic Cancer Tumouroids","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LIfT Biosciences"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"$12.0 million","newsHeadline":"F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"F-star Therapeutics"},{"orgOrder":0,"company":"pHion Therapeutics","sponsor":"Invox Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"pHion Therapeutics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Blue Earth Therapeutics"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail InfoWorks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"UK government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Pathios Therapeutics"},{"orgOrder":0,"company":"Ixaka","sponsor":"Alaya.bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alaya.bio Acquires Key Assets from Ixaka France, Accelerating the Progress of its Novel In Vivo CAR-T Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ixaka"},{"orgOrder":0,"company":"Cumulus Oncology","sponsor":"Eos Advisory","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Cumulus Oncology Raises \u00a39m in Seed Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cumulus Oncology"},{"orgOrder":0,"company":"NeoPhore","sponsor":"Sixth element capital","pharmaFlowCategory":"D","amount":"$39.5 million","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Raises an Additional \u00a39.6m (USD $12.2m) Series B Financing Extension to Further Progress Drug Discovery Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"NeoPhore"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$880.0 million","upfrontCash":"$10.0 million","newsHeadline":"Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Redx Pharma"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma Presents High Efficacy in Multiple Solid Tumor Models for its Next-Generation Cancer Drug Candidate and Synergy with Standard-of-Care Treatment in Liver Cancer Organoids","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Vidac Pharma"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Storm Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Oxilio has since progressed the product and now signed a significant service contract with Quotient Sciences, a drug development and manufacturing accelerator, to support the formulation development and preparation of clinical trials for OXL001.
METTL1 inhibits tumour growth and reduces tRNA methylation and stability of tRNAs. It displayed high selectivity over other RNA and protein methyltransferases.
VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.
Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS (Kirsten rat sarcoma virus) inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.
The net proceeds will be used to progress NeoPhore's lead canditate, NP1867, an oral, small molecule, first-in-class MMR inhibitor, through early pre-clinical development in solid tumours.
The proceeds will be used to accelerate the development of drug discovery programmes in the area of DNA damage response, towards clinical Proof of Concept.
Through the acquisition, Alaya.bio intends to leverage its combined assets to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered.
The grant funding will enable the company to expand its development of novel small molecule GPR65 inhibitors into the area of a possible treatment of malignant brain tumors.
Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells (CAR-T cells) in subjects with relapsed/refractory acute myeloid leukemia (AML).
In preclinical results to evaluate the binding affinity, lipophilicity, cellular internalization and therapeutic efficacy of 225Ac-rhPSMA-10.1 in preclinical models for the treatment of prostate cancer, using 177Lu-rhPSMA-10.